| scholarly article | Q13442814 |
| P2093 | author name string | D Robert Siemens | |
| Thomas A A Skinner | |||
| Angela Black | |||
| Dylan Hoare | |||
| P2860 | cites work | Molecular determinants of resistance to antiandrogen therapy | Q28236889 |
| Expression of follicle-stimulating hormone receptor in tumor blood vessels | Q28296174 | ||
| Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer | Q33944430 | ||
| The current state of hormonal therapy for prostate cancer | Q34129127 | ||
| The functional significance of FSH in spermatogenesis and the control of its secretion in male primates | Q34460860 | ||
| A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. | Q34631199 | ||
| Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues | Q35860959 | ||
| Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates | Q35981874 | ||
| Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer | Q36243296 | ||
| Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis | Q36309725 | ||
| Intermittent androgen suppression for rising PSA level after radiotherapy | Q36463238 | ||
| Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth | Q36876865 | ||
| Emerging therapies in castrate-resistant prostate cancer | Q37442526 | ||
| Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. | Q37533702 | ||
| New therapies for castration-resistant prostate cancer: efficacy and safety | Q37877007 | ||
| Gonadotropin Receptors and Regulation of Steroidogenesis in the Testis and Ovary | Q37896008 | ||
| The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies | Q38003528 | ||
| Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. | Q38602735 | ||
| Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer | Q40280423 | ||
| Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group | Q42636817 | ||
| Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer | Q42926024 | ||
| Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels | Q44479243 | ||
| Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy | Q44769706 | ||
| Mechanisms of androgen-refractory prostate cancer | Q45094999 | ||
| Reimbursement policy and androgen-deprivation therapy for prostate cancer | Q46147188 | ||
| Prostate—an extrapituitary source of follicle-stimulating hormone (FSH): Occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents | Q46982258 | ||
| Androgen receptors in endocrine-therapy-resistant human prostate cancer. | Q54296309 | ||
| Potential role of follicle-stimulating hormone (FSH) and transforming growth factor (TGFβ1) in the regulation of ovarian angiogenesis. | Q54643187 | ||
| Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR) | Q74450102 | ||
| P433 | issue | 3-4 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 122-127 | |
| P577 | publication date | 2015-03-01 | |
| P1433 | published in | Canadian Urological Association journal | Q26842808 |
| P1476 | title | Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer | |
| P478 | volume | 9 |
| Q28829239 | Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy |
| Q90903070 | Cell-based evidence regarding the role of FSH in prostate cancer |
| Q89284933 | Chemical vs Surgical ADT in Metastatic Prostate Cancer: A Comparison of Side Effects. Commentary on Comparison of Gonadotropin-releasing Hormone Agonists and Orchiectomy: Effects of Androgen Deprivation Therapy |
| Q33647728 | Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study |
| Q52905066 | Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study. |
| Q41764150 | Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects |
| Q47610526 | Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial |
| Q92707314 | Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT |
| Q47127295 | Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer. |
| Q92203321 | Switching from a gonadotropin-releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis |
| Q57105900 | Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer |
| Q38888796 | The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy |
| Q50053239 | Ursolic acid activates the apoptosis of prostate cancer via ROCK/PTEN mediated mitochondrial translocation of cofilin-1. |
| Q55068843 | Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL. |
Search more.